CompletedPhase 3ACTRN12607000421437

A clinical trial of a tooth cream in the repair of early dental decay.

A three-month, double-blind, parallel-group, placebo-controlled randomized clinical trial to investigate the remineralizing capacity of casein phosphopeptide-amorphous calcium phosphate in a post-orthodontic population.

Sponsor

GC Corporation

Enrollment

46 participants

Start Date

Aug 1, 2006

Study Type

Interventional

Conditions

Caries

Eligibility

Sex: Both males and femalesMin Age: 12 YearssMax Age: 18 Yearss

Inclusion Criteria3

Undergoing fixed orthodontic treatment and due to have appliances removed during study period.
Exhibiting a minimum of two WSLs on the buccal surfaces of teeth 14 to 44 (or 15 to 45 when first premolars have been extracted) at time of recruitment.
Able to attend for four visits over a 12 week period.

Exclusion Criteria7

a.Allergies to milk proteins.
b.Ulcerative mucosal conditions.
c.Chronic use of medication causing xerostomia.
d.Allergies to preservatives (or other ingredients) present in Tooth Mousse or placebo.
e.Unrestored dentinal caries in teeth 14 to 44 (or 15 to 45).
f.Pregnancy.
g.Any other illnesses/conditions that the Investigator deems could affect the study outcome.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Tooth Mousse (containing casein phosphopeptide-amorphous calcium phosphate nanocomplexes (CPP-ACP). Tooth Mousse contains 10% w/v CPP-ACP. Dosage is 1ml Tooth Mousse twice daily for 12 weeks.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000421437

Related Trials